FULC (Fulcrum Therapeutics, Inc.) Stock Financials & Earnings

FULCFulcrum Therapeutics, Inc.

Mkt Cap$436M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$75M

EPS (TTM)-$1.18

Free Cash Flow (TTM)-$60M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth-100.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$295K	-$16M	-$28M
Q2 23	$880K	-$17M	-$27M
Q3 23	$759K	-$17M	-$27M
Q4 23	$871K	$363K	-$28M
Q1 24	$0	-$479K	-$30M
Q2 24	$80M	$63M	$52M
Q3 24	$0	$0	-$25M
Q4 24	$0	-$369K	-$19M
Q1 25	$0	$0	-$20M
Q2 25	$0	-$300K	-$20M
Q3 25	$0	$0	-$22M
Q4 25	$0	$300K	-$23M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$17M	$11M	$657K	—
Q2 23	$18M	$10M	$616K	—
Q3 23	$18M	$9M	$640K	—
Q4 23	$19M	$10M	—	—
Q1 24	$19M	$10M	—	—
Q2 24	$17M	$10M	$271K	—
Q3 24	$15M	$8M	—	—
Q4 24	$11M	—	—	$8M
Q1 25	$13M	$7M	—	—
Q2 25	$13M	$7M	—	—
Q3 25	$14M	$8M	—	—
Q4 25	$15M	$7M	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$35M	$263M	$298M
Q2 23	$34M	$244M	$278M
Q3 23	$30M	$227M	$257M
Q4 23	$26M	$211M	$236M
Q1 24	$40M	$173M	$213M
Q2 24	$87M	$187M	$274M
Q3 24	$73M	$185M	$257M
Q4 24	$58M	$183M	$241M
Q1 25	$42M	$184M	$227M
Q2 25	$43M	$172M	$214M
Q3 25	$47M	$154M	$201M
Q4 25	$198M	$155M	$352M

Shares Outstanding

Revenue Per Employee

Revenue / Employee